BridgeBio Pharma, Inc.

bridgebio.com

What Do They Do?

Sells Attruby for adults with transthyretin amyloid cardiomyopathy and develops medicines for patients with genetic diseases.

How Do They Make Money?

Specialty pharmacies and distributors buy approved medicines, and BridgeBio earns product revenue when they obtain the products. Licensing arrangements bring upfront and milestone payments; commercial partners also generate royalties on product sales.

FY2025 revenue by product or service revenue

Segment	Share	How money arrives
Net product revenue Sold outright	72% FY2022: 2.0%	Sold outright
License and services revenue Licensed	26% FY2022: 98%	Licensed
Royalty revenue Licensed	2.3%	Licensed

Who Are Their Customers?

Specialty pharmacies and specialty distributors are its main product customers. In Europe and Japan, Bayer and Alexion commercialize Beyonttra, while BridgeBio sells directly in some international markets.

Do Revenues Turn Into Profits?

No. It lost $732.9M in FY2025.

Operating income, FY2025

−104% of revenue

▼ −12% (Loss) vs FY2024 (−$593M, −267%)

Net income, FY2025

−146% of revenue

▲ +35% (Loss) vs FY2024 (−$543.3M, −245%)

Free cash flow, FY2025

−89% of revenue

▼ −14% (Loss) vs FY2024 (−$521.7M, −235%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +120%; vs $110.6M in Q2 FY2025
Net income: ▼ −15% (Loss); vs −$183.8M in Q2 FY2025

Net product revenue share of revenue vs 64.7% in Q2 FY2025

Aug 31, 2026 Agrees with U.S. government to expand Medicaid access to Attruby The voluntary agreement expands state Medicaid access to Attruby through the GENEROUS Model.

Growing. Revenue grew 7.2x in 4 years, from $69.7M in FY2021 to $502.1M in FY2025, about 64% a year.

Acquired a marketed product The earlier report described acoramidis as under clinical development; the latest says BridgeBio markets it in the United States as Attruby after approval.

Oncology moved outside the core portfolio The earlier report included a KRAS inhibitor portfolio for cancers; the latest describes BridgeBio Oncology Therapeutics as a separate spun-out company in which BridgeBio retains an equity interest.

Revenue over time

Net product revenue License and services revenue Royalty revenue

$1B$500M$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Pfizer, Alnylam Pharmaceuticals, Ascendis Pharma, Tyra Biosciences, Ribomic, and BioMarin Pharmaceutical

Comments